Daniele Santini | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study	ONCOTARGET	2016
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR"	CANCER TREATMENT REVIEWS	2016
Adjuvant bisphosphonates in early breast cancer. Consensus guidance for clinical practice from a European Panel	ANNALS OF ONCOLOGY	2016
Procalcitonin as diagnostic marker of infection in solid tumors patients with fever	SCIENTIFIC REPORTS	2016
Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology	EXPERT OPINION ON DRUG SAFETY	2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study	PLOS ONE	2016
Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3	EUROPEAN UROLOGY	2016
Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain	JOURNAL OF CLINICAL ONCOLOGY	2016
Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases	SCIENTIFIC REPORTS	2016
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis	ONCOTARGET	2016
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2016
Treatment of advanced renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE	2016
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?	TARGETED ONCOLOGY	2016
Drug-induced hepatotoxicity in cancer patients - implication for treatment	EXPERT OPINION ON DRUG SAFETY	2016
Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2016
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2016
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer	FUTURE ONCOLOGY	2016
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy	SCIENTIFIC REPORTS	2016
New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	2016
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?	ONCOTARGET	2016